In addition to the sale, Catriona acquired 9,074 shares through stock option exercises at a price of $21.1 per share, amounting to a total of $191,461. These transactions reflect ongoing changes in Catriona’s holdings in the company. The company maintains a strong financial position with more cash than debt on its balance sheet and a current ratio of 17.25. InvestingPro subscribers can access 8 additional key insights about AKRO’s financial health and market performance. The company maintains a strong financial position with more cash than debt on its balance sheet and a current ratio of 17.25. InvestingPro subscribers can access 8 additional key insights about AKRO’s financial health and market performance.
In addition to the sale, Catriona acquired 9,074 shares through stock option exercises at a price of $21.1 per share, amounting to a total of $191,461. These transactions reflect ongoing changes in Catriona’s holdings in the company.
In other recent news, Keros Therapeutics has paused dosing in certain arms of its Phase 2 TROPOS Trial due to unexpected cases of pericardial effusion among participants. The trial, evaluating the safety and efficacy of cibotercept in patients with pulmonary arterial hypertension, will continue dosing at the 1.5 mg/kg level. Keros plans to present topline data from all treatment arms of the trial in the second quarter of 2025.
On the other hand, Akero Therapeutics (NASDAQ:) has received a positive outlook from Citi, which initiated coverage on the company’s stock with a Buy rating. The rating is based on the potential of efruxifermin, Akero’s treatment for metabolic dysfunction-associated steatohepatitis (MASH), to be a leading therapy in the market, particularly for cases with moderate to advanced fibrosis.
Furthermore, Akero reported positive results from its Phase 2b HARMONY study of efruxifermin for MASH. The study revealed that over 40% of participants showed regression of liver fibrosis after 96 weeks of treatment. Additionally, 30% achieved near-complete reversal of MASH-related disease with EFX 50mg.
Akero has also made strides with its Phase 3 SYNCHRONY Outcomes trial for MASH patients with compensated cirrhosis. The trial, which plans to enroll approximately 1,150 patients, has already dosed its first patient. Investors are also awaiting the Week 96 data release from the ongoing Phase 2b SYMMETRY study, expected in the first quarter of 2025. These are the latest developments in the companies’ ongoing efforts to address significant health challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
